Pipeline

Symbionyx research and development is devoted to new medicines that provide therapeutic benefit to patients worldwide.  Combining creativity, scientific rigor, and extensive knowledge of autoimmune disorders to bring medicine to patients.

Isosorbide di-(methyl fumarate) (IDMF)

Isosorbide di-(methyl fumarate) is a molecule with both anti-inflammatory and antioxidant properties. IDMF has been designed to have a bioactivity profile that is similar to or enhanced compared to Dimethyl Fumarate (DMF).

IDMF represents a novel molecule targeting two large patient populations (psoriasis and multiple sclerosis) suffering from chronic, recurring disease, where even with numerous products available there remains an unmet need for more efficacious and safer treatments. IDMF has been shown to be effective and safe in pre-clinical in vitro and animal models. It does not sensitize the skin and thus can be used as a topical treatment for psoriasis or oral treatment for both psoriasis and multiple sclerosis.

The invention is protected by composition of matter and application patents – US (US 9,636,321) and Europe (EP 3273951 B1) – as well as multiple pending patents.

Isosorbide di-(linoleate/oleate) (IDL)

Moisturizing agents are commonly used as steroid-sparing therapies for xerotic skin. IDL provides occlusion and additionally influences gene expression patterns that govern skin physiology. Consistent with this, our clinical study demonstrates that IDL buffers against TEWL and was also accompanied by improvements in skin hydration that, with long-term treatment, may help resolve pruritus, limit erythema, and reduce the risk of secondary infections (NCT04253704).

This study supports the efficacy of IDL as unique treatment option with dual mechanism of action which combines a corticosteroid-like anti-inflammatory effect with changes in epidermal bioactivity that promote keratinocyte differentiation to restore skin barrier function.

Proof of concept clinical study is currently underway. The goal of this study is to assess the use of isosorbide diesters (IDEAS), for eczema and if it can reduce the need for the use of topical steroids (NCT04831892.).

The invention is protected by composition of matter and application patents – US (US 10,597,402) and Europe (EP 3503866) – as well as multiple pending patents.